Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
about
Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisInhaled steroids and risk of pneumonia for chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta 2 -agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseA rational approach to single, dual and triple therapy in COPDThe association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysisAppropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawalDrug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.COPD exacerbations. 4: PreventionCanadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 updateThe role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD.Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation.AIMAR survey on complex forms of bronchial asthma and COPD, their management and perception of critical issues.Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.Inhibition of granulocyte migration by tiotropium bromideIncident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids?Withdrawal of inhaled corticosteroids in individuals with COPD--a systematic review and comment on trial methodology.Prognostic Value of the Six-Second Spirometry in Patients with Chronic Obstructive Pulmonary Disease: A Cohort StudyOutcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroidsFactors associated with the prescription of inhaled corticosteroids in GOLD group A and B patients with COPD - subgroup analysis of the Taiwan obstructive lung disease cohort.The Prognostic Value of Residual Volume/Total Lung Capacity in Patients with Chronic Obstructive Pulmonary DiseaseCost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease.Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practicePrediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease.Outcome of Inhaler Withdrawal in Patients Receiving Triple Therapy for COPD.Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial.Update in chronic obstructive pulmonary disease 2005.Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management.The role of combination therapy with corticosteroids and long-acting beta2-agonists in the prevention of exacerbations in COPDPharmacological treatment of chronic obstructive pulmonary disease.Comparison and optimal use of fixed combinations in the management of COPD.Salmeterol/fluticasone combination in the treatment of COPD.Fixed combination therapies in COPD--effect on quality of lifeOne-year treatment with mometasone furoate in chronic obstructive pulmonary diseaseAssociation of Inhaled Corticosteroids with Incident Pneumonia and Mortality in COPD Patients; Systematic Review and Meta-Analysis.The Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.Cost-effectiveness of combination therapy for chronic obstructive pulmonary diseaseTreating patients with respiratory disease who smoke.
P2860
Q24197853-A75456C3-BB1A-4D5C-A4C7-B001F02E6EF6Q24197989-8A6C7657-D40D-4EA6-BD6B-4FB40E9C603BQ24202510-C34BE8EE-9E53-4304-8ABD-42A93F752727Q24243564-AF6B0E74-2041-439B-8665-28026CAFDEAFQ26776477-FE2CB138-8F5A-4198-B3FE-B0FD0B838E42Q28070325-16BCCDB4-0E44-48EB-892F-B8E3A594FF74Q28074169-DDDA2F6F-B2EB-4644-BA28-0B805ADA1BEFQ30249747-59D2E773-6F34-4A31-89A3-09FB43614ABEQ30480789-14146229-AD0D-4590-AC65-2133C6B0B90FQ33591899-2B446733-B888-424D-827C-7202FDE74469Q33966009-4A367AF6-29D6-4581-A70B-1EFD4564E830Q34003435-2C88E3C7-C3CE-4355-B956-99DAE5425AE3Q34065276-440C91C4-47BF-428A-A10A-67F12A3624A8Q34252132-C43682AC-D76D-4BDF-96DA-9F39FE2B9031Q34514828-96BC5597-76F5-4A34-ABBE-BC87BD9A4A0CQ34550471-A87FDBE5-DF06-4F20-9388-90C56A66DCF0Q34638204-EF79EBFE-FD5D-4554-9CC6-997EDC97AD1CQ35140742-51530989-33D8-4FF9-A421-369A105C0B31Q35257612-9465A03D-C859-4BDD-8EBC-C4C5A8990D92Q35816307-09F792B0-27B9-48EB-9170-DE838452D7C4Q35876509-560428B9-8A5C-4F2F-BAA9-FF5E40803275Q36072536-A235188A-72A8-4F82-8E09-81ACC843C218Q36075457-6F06431B-DCB5-4F13-822E-616FA36044B8Q36148623-F46F3A8E-23FF-4E20-B68F-9ABE0000A019Q36332206-4519C6E3-A175-4D63-9AE7-B28CEA213296Q36388372-61C76277-0C49-495A-8139-E49CA7118D2CQ36431478-790DF018-F026-4861-9125-0E9686F9273CQ36464679-387B4844-7040-4998-BC81-3C5ABD5D404FQ36470462-BC4E92CF-21AD-40EB-85BE-70C81D8EB159Q36907742-FFB764ED-F9C9-48B1-8B18-F3F2A4943CDFQ37017315-B8EDD34C-E1A0-4613-AFF5-537AA03B09EAQ37017344-A2B5904F-1F47-4549-8D25-17091EDF6BA8Q37017520-145BF183-3F93-4C5D-94B4-9AD56858E38FQ37018817-D2091CA3-627F-4C1B-ABC5-5D824278A8B0Q37082607-F2AE7151-E999-4B3F-9C27-90DA18C9C090Q37101342-EF6286CE-8A75-4DAD-AE56-0CC23D257971Q37109222-93EF5E4E-69E1-4B94-810B-4E2F0775A64DQ37128138-3231553D-3FFB-4832-96DE-37D9FD76DB07Q37192340-C5A8E94D-BC45-41BD-9256-2ED8EEE6CA7DQ37362600-40142CF1-3D50-44A1-8DF5-2976C2EFED8B
P2860
Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Withdrawal of fluticasone prop ...... a randomised controlled trial.
@ast
Withdrawal of fluticasone prop ...... a randomised controlled trial.
@en
type
label
Withdrawal of fluticasone prop ...... a randomised controlled trial.
@ast
Withdrawal of fluticasone prop ...... a randomised controlled trial.
@en
prefLabel
Withdrawal of fluticasone prop ...... a randomised controlled trial.
@ast
Withdrawal of fluticasone prop ...... a randomised controlled trial.
@en
P2093
P2860
P356
P1433
P1476
Withdrawal of fluticasone prop ...... a randomised controlled trial.
@en
P2093
A F Kuipers
C A J Hensing
COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group
D S Postma
E C Creutzberg
E F M Wouters
P2860
P304
P356
10.1136/THX.2004.034280
P407
P577
2005-06-01T00:00:00Z